

SensoLyte[™] Anti-Human βeta-Amyloid (1-40) Quantitative ELISA*Colorimetric*

Revision 1.2 Last updated: July 2020

| Catalog # | AS-55551 |
|-----------|-------------------------|
| Kit Size | One 96-well strip plate |

This kit is optimized to detect human beta-Amyloid (1-40) peptide in human brain lysate, transgenic mouse brain lysate, human cerebrospinal fluid, plasma, or saliva. Wells are pre-coated with monoclonal anti-beta-Amyloid (1-40) specific capture antibodies and blocked with a proprietary blocking solution. The amount of human beta-Amyloid (1-40) is quantified using ELISA. Ample materials and reagents are provided to perform 96 assays.

- Convenient Format
 - Pre-coated and pre-blocked 96-well strip plate
 - o Ready-to-use substrate solution and other assay components
 - o One step assay (samples and detection antibodies are added simultaneously)
 - 1 hour assay time at room temperature (excluding incubation)
- High Sensitivity
 - Detects as low as 2 pg/ml (13 fmoles/ml) of human beta-Amyloid (1-40)
- Broad Dynamic Range
 - o 3.9-250 pg/ml of human beta-Amyloid (1-40) peptide

Kit Components and Handling

| Component | Description | Quantity |
|-------------|--|--------------------|
| Component A | Mouse monoclonal anti-beta-Amyloid (1-40) coated plate | 12 x 8-well strips |
| Component B | Human beta-Amyloid (1-40) Peptide Standard (lyophilized) | 1 μg |
| Component C | 1 X Sample Dilution Buffer | 60 ml |
| Component D | 10 X Wash Buffer | 30 ml |
| Component E | TMB Color Substrate Solution | 10 ml |
| Component F | Stop Solution | 10 ml |
| Component G | Peptide Standard Reconstitution Buffer | 1 ml |
| Component H | Detection Antibody (Rabbit anti-Human beta-Amyloid-HRP) | 50 μl |
| Component I | 1 X Detection Antibody Dilution Buffer | 10 ml |
| Component J | Adhesive Plate Covers | 2 pieces |

Other Materials Required (but not provided)

- Microplate reader: Capable of reading absorbance at 450 nm
- Rocking platform or shaker
- Strip ejector (to eject strips for future assay if not all strips are used in one experiment)
- Plate washer (optional)

Shipment and Storage

- Kit is shipped on blue ice. Upon receipt, store all kit components at 2-8 °C for up to 6 months
- Reconstituted Peptide Standard (Component B) must be stored at –80 °C in small aliquots

For research use only! Not for diagnostic use!

Introduction

Alzheimer's Disease (AD) is the most common neurodegenerative disorder in elderly people. It has been demonstrated that AD has biological cause and is characterized by the presence of senile plaques and neurofibrillary tangles mainly in cerebral cortex and hippocampus brain regions. ¹⁻⁵ Beta-Amyloid (1-40) (A β 40) and beta-Amyloid (1-42) (A β 42) are the main components of the above plaques; however, other forms of beta-Amyloid peptides are also present. Both peptides are cleaved from the Amyloid Precursor Protein (APP) by β -secretase and γ -secretase enzymes. ^{2,3,5} Many studies suggest that A β 42 or/and A β 43 are required to initiate formation of amyloid plaques and neurofibrills that leads to the neurodegeneration, ¹⁻⁵ while A β 40 is less neurotoxic. Recently, increased levels of beta-Amyloid (1-42) peptide in human saliva were identified in mild Alzheimer's disease patients⁶. It may be possible to use saliva level of beta-Amyloid peptides to assess higher risk of acquiring Alzheimer's disease in the future or to monitor disease progress.

The SensoLyte® beta-Amyloid (1-40) Quantitative ELISA Kit (Human) provides a convenient and quantitative assay for determining human A β 40 amount in cell and tissue lysate as well as in body fluids. Compared to other anti-human A β 40 ELISA kits on the market, it takes less time to run this assay. HRP conjugated detection antibody in this kit is added simultaneously with samples and standards during the assay. This eliminates extra incubation and washing steps and makes this kit one-step procedure for A β 40 quantification.

Experimental Protocol

Please Note:

- a) Bring kit components to room temperature before starting the assay
- b) Spin down all components with volume less than 100 µl before use
- c) Mix the Washing Buffer (Component D) to dissolve any precipitated salt

1 ELISA Protocol:

- 1.1 Reconstitute human beta-Amyloid (1-40) Standard (Component B) with 1 ml of Peptide Standard Reconstitution Buffer (Component G). Allow peptide to hydrate for ten minutes. Mix gently by inversion. Aliquot the reconstituted standard in 100 μl per vial (vials are not provided with the kit), label, and save unused Aβ40 standard at –80 °C. We recommend using glass vials such as borosilicate for storage of the reconstituted standard to avoid absorption of Aβ40 to plastic surfaces. **Do not reuse reconstituted standard once it is thawed.**
- 1.2 Arrange and label strips (Component A) based on the number of wells for standards and samples. Although diluted standards and samples can be run as single points, duplicates are recommended. Place unused strips into the supplied bag, seal completely, and store at 4 °C.
- 1.3 Prepare serial dilution of the human Aβ40 standard immediately before use. Refer to the table below.

| Step | Concentration, pg/ml | Aβ40 Standard (Component B) | Sample Dilution Buffer (Component C) |
|------|----------------------|--------------------------------|--------------------------------------|
| 1 | 1,000,000 | Prepare | as described in 1.1 |
| 2 | 10,000 | 10 µl from step 1 | 990 µl |
| 3 | 250 | 25 µl from step 2 | 975 μl |
| 4 | 125 | 500 µl from step 3 | 500 μl |
| 5 | 62.5 | 500 µl from step 4 | 500 μl |
| 6 | 31.25 | 500 µl from step 5 | 500 μl |
| 7 | 15.625 | 500 µl from step 6 | 500 μl |
| 8 | 7.8125 | 500 µl from step 7 | 500 μl |
| 9 | 3.91 | 500 µl from step 8 | 500 μl |

1.4 Dilute Detection Antibody (Component H) 200 fold in Detection Antibody Dilution Buffer (Component I). Prepare 50 µl of the above antibody solution for each well to be run in the assay. One strip requires 0.5 ml of the diluted detection antibody solution.

- 1.5 Add 100 μl per well of the diluted Aβ40 standards (Starting with Step 3 from 1.3) in duplicates including blank. We recommend diluting plasma at 1:20 ratio and CSF at 1:4 ratio with 1 X Sample Dilution Buffer to avoid sample matrix effects. For transgenic mouse brain lysate it is recommended to use 1:100 dilution ratio for young mice (5-10 weeks old) and 1:400 dilution ration for older mice (10-15 weeks old). In addition, Protease inhibitor cocktail with PMSF must be added to all samples to avoid protein degradation (a recipe example is provided in the **Appendix** section).
- 1.6 Add 100 µl of the diluted samples into appropriate wells.
- 1.7 Add 50 µl of the diluted detection antibody solution (from Step 1.4) into each well to be assayed, apply Adhesive Plate Cover (Component J), and incubate plate overnight at 4°C. **Protect wells from the light.**
- 1.8 Prepare 1X working wash buffer by diluting the 10 X Wash Buffer (Component D) with deionized H₂O.
- 1.9 After plate incubation, aspirate the wells and wash them with 350 µl/well of 1x wash buffer 6-7 times. Allow 20 seconds soaking time before emptying the wells between washes. Pat dry the plate using a paper towel and wipe clean outside of wells with non-abrasive paper to ensure accurate optical reading.

Insufficient washing will increase background reading.

- 1.10 Add 100 μl of the TMB Color Substrate Solution (Component E) into each well. Tap plate gently and incubate at room temperature until blue gradient is clearly observed across the wells (5- 15 min). It may be necessary to adjust color development time so that absorbance values will fall within the detection range. Samples may require further dilution if Aβ40 concentration is too high.
- 1.11 Add 50 µl of the Stop Solution (Component F) into each well and tap plate gently (blue color will turn to yellow).
 Measure absorbance (OD) at 450 nm using a microplate absorbance reader within 20 minutes after adding the Stop Solution.

2. Calculate the concentration of Aβ40 in samples.

- 2.1 Determine the average values (if replicates are used) for the Aβ40 standard and sample absorbance readings. Plot calibration curve using Linear Regression curve-fit. R² should be higher than 0.98. There should be at least 5 standard concentrations in the calculation to ensure statistical significance. The reading for the highest standard concentration (250 pg/ml) can be excluded from the curve if signal is too strong.
- 2.2 Choose absorbance values for the diluted samples that are within the range used in the Aβ40 standard curve, and calculate the concentration of human Aβ40 in the tested sample(s). Calculated concentrations must be multiplied by the sample dilution factor.
- 2.3 Typical Aβ40 Standard Curve:

Please note, new standard curve must be generated each time when the assay is run.

Note: 1) Standards were run in duplicates, blank value was subtracted, and 250 pg/ml point was excluded from the standard curve graph.

2) Aβ42 data is shown for cross-reactivity purpose.

| Aβ40, pg/ml | OD @ 450 nm, Aβ40 | OD @ 450 nm, Aβ42 |
|-------------|-------------------|-------------------|
| 250 | 3.566 | 0.072 |
| 125 | 2.136 | 0.031 |
| 62.5 | 1.216 | 0.01 |
| 31.25 | 0.588 | 0 |
| 15.6 | 0.279 | 0 |
| 7.8 | 0.135 | 0 |
| 3.9 | 0.064 | 0 |
| 0 | 0 | 0 |




Figure 1. An example of the human Aβ40 ELISA standard curve.

3. Kit Performance.

3.1 <u>Aβ40 Recovery Test:</u>

Human A β 40 was added to the diluted human fluids and assayed using the kit

| Specimen | Theoretical Value, (pg/ml) | Measured Value, (pg/ml) | % Recovery |
|--------------------|----------------------------|-------------------------|------------|
| Human Plasma (X20) | 10 | 10.9 | 109 |
| Human Plasma (X20) | 40 | 42.35 | 105.8 |
| Human CSF (x4) | 10 | 10.7 | 107 |
| Human CSF (x4) | 25 | 25 | 100 |

Note: 1. Human plasma was diluted 1:20 and human cerebrospinal fluid (CSF) was diluted 1:4 with Sample Dilution Buffer

3.2 Intra-Assay Variation Test:

| Measurement | Standard | Coefficient of | n |
|----------------|-----------|----------------|----|
| Value, (pg/ml) | Deviation | Variation, % | |
| 10 | 0.74 | 6.8 | 10 |

3.3 Cross Reactivity Test:

| Peptide | Cross Reactivity, % |
|------------|---------------------|
| Human Aβ40 | 100 |
| Human Aβ42 | <1.5 |
| Human Aβ37 | <0.5 |
| Human Aβ28 | <0.1 |

Note: All tested peptides were added at 125 pg/ml concentration.

^{2.} Each spiked value was assayed 5 times

Appendix

1. Buffer composition for transgenic mouse (i.e. TG2576) brain homogenate:

5M Guanidine HCI 50 mM Tris HCI, pH=8.0

Mix 800 μ l of the above solution with 100 mg of mouse brain sample in a Dounce homogenizer placed on ice. Homogenize the tissue thoroughly and incubate at room temperature for 3-4 hours with mixing. Guanidine-HCl brain homogenates are stable at 4 °C for several weeks and can be freeze-thawed many times without degradation of beta-Amyloid peptides.

Dilute brain homogenate with "Sample Dilution Buffer" (Component C) for the assay. We recommend 1:100 dilution ratio for young mice (5-10 weeks old) and 1:400 dilution ratio for older mice (10-15 weeks old) to start with for transgenic mouse brain homogenate. User should determine the optimal dilution factor. Transgenic mouse brain lysates require higher dilution factor due to the high concentration of Aβ40 peptide present in the brain. **Guanidine-HCl concentration higher than 0.125M will result in a significant loss of signal in the assay.**

2. Protease Inhibitor Cocktail Recipe (100 X concentrate)

 $\begin{array}{ll} \text{Aprotinin} & 0.4 \text{ mg} \\ \text{Leupeptin} & 2 \text{ mg} \\ \text{Deionized H}_2\text{O} & 900 \text{ }\mu\text{I} \end{array}$

Dissolve 0.1 mg of Pepstatin A in 100 µl of methanol and mix with the above solution.

Aliquot and store cocktail at -80 °C.

3. 100 mM PMSF Solution (100 X concentrate):

Dissolve 174 mg of PMSF in 10 ml of pure isopropanol, aliquot, and store at -80 °C. Add to the protease inhibitor cocktail (1mM final concentration) just prior to use.

References:

- 1. Levites Y. et al., The Journal of Clinical Investigations 116(1): 193-201: 2006
- 2. Broersen K. et al., Alzheimer's Research and Therapy 2: 1-14, 2010
- 3. Zhang Yun-Wu, et al., Molecular Brain 4: 1-13: 2011
- 4. Koechling T., et al., Int. Journal of Alzheimer's Disease, 2010
- 5. Bobba A., et al., Int. Journal of Alzheimer's Disease, 2010
- 6. Bermejo-Pareja F., et al., BMC Neurology, 2010